<DOC>
	<DOCNO>NCT02302950</DOCNO>
	<brief_summary>Raltegravir first market strand-transfer inhibitor HIV-1 FDA approve 2007 . It currently one prefer treatment regimen HIV Department Health Human Services . It become widely used antiretroviral therapy option HIV infect patient . It provide good tolerability favorable lipid profile patient compare antiretroviral treatment option . Little data report efficacy minority patient population . Moreover , data indigent minority population United States aggregate . Therefore study investigate efficacy raltegravir minority woman reside Houston , TX HIV infect .</brief_summary>
	<brief_title>A Retrospective Analysis Raltegravir Use Minority HIV Infected Women Houston , Texas</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . HIVinfected woman pick raltegravir year 2013 Thomas Street Health Center . 2 . Minority woman Black/African American , Hispanic/Latino</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>raltegravir use</keyword>
	<keyword>woman</keyword>
</DOC>